In partnership with
From The Desk of
Matt dives into a specific healthcare topic to help those in the industry, and those outside of it, better understand the market drivers causing today’s healthcare challenges.
The Denial Letter Was Written Six Months Ago
The denial letter your patient just received existed before the prescription did.
A benefits consultant and a pharmacy benefit manager drafted the logic six months earlier, in a meeting your patient never knew happened. Both sides held undisclosed financial relationships with each other. The patient pays. Everyone else profits. Welcome to the architecture nobody puts on the launch slide.
Most pharma launch teams still treat denials as a clinical evidence problem. They send the medical affairs team to argue the science. They train the field to overcome objections. They build appeal letter templates. None of it matters, because the denial got written upstream of any clinical conversation. The fight ended before anyone noticed it started.
If you work in market access, patient advocacy, or HR benefits, the rest of this post will sting. Read it anyway.
The Conflict Architecture Nobody Disclosed
STAT News documented the consultant-PBM payment architecture in 2023. Rebate sharing. Administrative fees. Preferred vendor relationships. Money flowing from PBMs back to the consulting firms employers hired to evaluate those same PBMs. The "neutral advisor" your HR director trusts often runs on undisclosed PBM revenue.
This matters because of scale. Healthcare administrative spending consumes roughly one trillion dollars annually, about a quarter of every healthcare dollar in America. CMS projects healthcare spending will hit twenty percent of GDP by 2033. We pour a quarter of every dollar into the machinery that decides who gets care, and a meaningful slice of that machinery gets paid by the entities it pretends to oversee.
Two more data points sharpen the picture.
ELAVAY 2025 trend data showed that companies with high-trust patient advocacy partnerships outperformed peers on access metrics regardless of where their drug sat on the price spectrum. Price did not predict access. Relationships did.
BIOADVOCATE Benchmark data show the same thing from a different angle. The gap between advocacy organizations' actual influence and patient outcomes remains the single largest unaddressed lever in commercial market access. Companies measure ten things that move outcomes by two percent and ignore the one thing that moves outcomes by twenty.
The conflict architecture survives because almost nobody in the room has an incentive to map it. Now let me name the players.
Where Patients Lose
I want to call specific roles by name. No generalizations. If you recognize yourself in this section, that recognition is the work.
Benefits consulting firms present as neutral advisors while collecting PBM revenue. They sit across from HR leaders, recommend "preferred" vendors, and pocket fees from the vendors they recommend. The conflict gets disclosed in fine print or never. Most clients never ask.
HR leaders sign off on benefit designs without the tools to interrogate them. Many genuinely want to do right by employees. Nobody trained them to ask which PBM contract terms hide spread pricing, which formulary tiers track rebate revenue rather than clinical evidence, or which step therapy protocols exist purely to delay utilization. They trust the consultant. The consultant gets paid by the PBM.
PBMs write formulary criteria that align with their financial relationships rather than patient needs. Rebate-driven tier placement. Step therapy designed to push patients toward the molecules with the richest manufacturer rebates, not the best clinical fit. Prior authorization criteria that read like clinical guidelines and function like cost containment.
Pharma launch teams treat prior authorization like a clinical evidence problem. They commission more health economic data, build slicker dossiers, train the field harder. Meanwhile the denial logic that will block their launch got written six months earlier in a benefits design meeting they never attended.
Patient advocacy organizations stand outside the appeals architecture they should own. Most run on philanthropic fumes. The ones with funding rarely have the denial pattern data they need to act with precision. The ones with the data rarely have the funding to scale a response. The structural exclusion serves everyone except patients.
Health plan members get denials, step therapy mandates, and surprise bills they never voted for. They blame their doctor. They blame the manufacturer. They almost never blame the consultant who designed the plan or the PBM that wrote the formulary. The architecture protects itself through obscurity.
Six failures. Six roles. Every one of them fixable. The companies that fix them win.
Healthcare’s biggest conflict is not hidden. It is normalized.
What Top-Tier Companies Do Instead
ELAVAY top-tier movers in 2025 did not have better drugs. They had better architecture. Five behaviors separated them from the field.
They invest in advocacy as a market-access function, not as a corporate communications line item. The advocacy team reports into commercial. The advocacy team has a budget that scales with the launch. The advocacy team sits in the room when the access strategy gets built, not after it gets approved.
They build relationships with advocacy organizations that influence patient appeals before launch, not after the first wave of denials. They fund the operational capacity those organizations need. They co-develop denial response playbooks. They show up in year one of the partnership and stay through year five.
They share denial pattern data with their advocacy partners and trust those partners to act on it. Most companies hoard the data, citing legal, compliance, or "competitive" concerns. The top-tier movers found ways to share it that satisfied legal review and accelerated patient access. Trust scales. Hoarding kills outcomes.
They train commercial teams to map the conflict architecture before they finalize launch plans. Which consultants serve the top three priority plans? Which PBM relationships drive formulary placement? When does the benefit design cycle close for the launch year? Top-tier teams answer those questions before they finalize anything.
They use the Advocacy Influence Diagnostic to surface internal gaps quantitatively, and then they fix them. Not a survey. A diagnostic. The companies that scored in the top quartile in 2025 did the work in public view. They published their gaps. They closed them. They reported the results.
None of these behaviors requires a bigger budget. They require honest internal conversation and the willingness to act on what the data says.
Your competitor just replied. You're still typing.
A lead comes in on Instagram. Another on Messenger. Three more on SMS.
Your team switches tabs, repeats answers, and loses context while hot leads wait hours for replies. At 2am, nobody responds at all.
That’s not a people problem. It’s a process problem.
Wati brings Instagram DM, Facebook Messenger, TikTok, WhatsApp, SMS, RCS, and web chat into one AI-powered inbox. Automations instantly respond, qualify leads, and route conversations to the right person, 24/7.
Your team stops firefighting. Your leads stop waiting. Your pipeline starts moving.
Build the Bridge Before You Need It
Three audiences. Three actions.
If you run market access at a pharma or biotech company, stop writing your strategy as a clinical conversation. The clinical case matters, and it loses every fight where the architecture moves first. Map the consultant and PBM dependencies for your top three priority plans before your next launch meeting. Bring the map to the meeting. Watch what changes.
If you lead a patient advocacy organization, build your appeals infrastructure now. The current pricing environment gives you the strongest case you have ever had for funded denial-pattern surveillance. Pharma partners want to invest. Health systems want a partner. Stop treating capacity-building as a future-state problem. The future arrived last quarter.
If you sit in HR or run employer benefits, ask your benefits consultant who pays them. Get the answer in writing. Ask for the rebate flow disclosures. Ask for the preferred vendor disclosures. Ask whether their compensation depends on which PBM you select. If the answer arrives slow or is vague, you have your answer.
Three more questions HR leaders should ask out loud in their next consultant meeting. Which formulary decisions on this plan get driven by rebate revenue rather than clinical evidence? What percentage of our covered lives sit on a step therapy protocol that delays first-line therapy by more than thirty days? How many of our denied claims get appealed, and what percentage of appeals succeed? Three questions. Each one exposes a slice of the architecture. None of them requires legal expertise to ask.
A note for everyone reading. The architecture survives not because the people inside it want patients to suffer. It survives because each role optimizes locally and nobody owns the system. Consultants optimize for client retention. PBMs optimize for rebate capture. HR leaders optimize for cost predictability. Pharma launch teams optimize for clinical narratives. Advocacy organizations optimize for the missions they can fund. Each rational actor pulls the system further from the patient.
That pattern breaks when one role refuses to play. A consultant who discloses in writing breaks it. An HR director who asks the three questions breaks it. A pharma launch team that maps the conflict architecture breaks it. An advocacy organization that builds funded appeals infrastructure breaks it. The system does not require permission to fix itself. It requires somebody in the room to move first.
Take the Advocacy Influence Diagnostic at https://aid.elavay.com/survey to see exactly where your function stands. The 2026 ELAVAY Brain Health Report is now available, with the ELAVAY: Advocacy Intelligence report becoming available this month. Reach out to [email protected] to see how your organization performed.
The denial letter your patient receives six months from now exists somewhere in a draft conversation right now. Find that conversation. Get in the room.
That work starts today, not after the next launch.